A recently developed TIM-3/PD-1 bispecific antibody, lomvastomig, has demonstrated superior antitumor activity compared with monotherapy in treating αPD-1–resistant NSCLC, and is currently being evaluated in a phase 1 clinical trial in NSCLC patients (112). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.